Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma

Kvaternick, Valerie; Malinski, Thomas J.; Wortmann, Jill; Fischer, James B.

doi:10.1016/j.jchromb.2007.04.037

Cited by 27 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Short-term (benchtop) stability of firocoxib in urine was assessed for fortified samples maintained at room temperature for at least 4 h following one F/T cycle. Stability of firocoxib in plasma was assessed previously in our laboratory [21]. Firocoxib was stable in plasma for at least eight F/T cycles.…”

Section: Stabilitymentioning

confidence: 99%

“…Previously, there were no published methods for the quantitation of firocoxib in plasma. A method to determine the concentrations of firocoxib in plasma, developed and validated in our laboratory, has been submitted for publication [21]. This method uses solid phase extraction followed by LC-UV analysis and has a LLOQ of 25 ng/mL in horse and dog plasma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Automated liquid chromatography–tandem mass spectrometry method for the analysis of firocoxib in urine and plasma from horse and dog

Letendre¹,

Kvaternick²,

Tecle³

et al. 2007

Journal of Chromatography B

Self Cite

View full text Add to dashboard Cite

Section: Stabilitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Automated liquid chromatography–tandem mass spectrometry method for the analysis of firocoxib in urine and plasma from horse and dog

Letendre¹,

Kvaternick²,

Tecle³

et al. 2007

Journal of Chromatography B

Self Cite

View full text Add to dashboard Cite

“…17,18 Firocoxib is approved for the control of pain and inflammation associated with OA for up to 14 days. Firocoxib in a paste form (also available in injectable form) has become a commonly prescribed treatment of clinicians for long-term treatment of OA, and more specifically chronic OA.…”

Section: Donnell and Frisbiementioning

confidence: 99%

Use of firocoxib for the treatment of equine osteoarthritis

Donnell¹,

Frisbie²

2014

VMRR

View full text Add to dashboard Cite

This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E 2 remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E 2 from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1-3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date.

show abstract

“…Chemically it is a 3-cyclopropymethoxy-5,5-dimethyl-4-[4-(methyl sulfonyl) phenyl]-2-(5H)-furanone and its molecular weight is 336.402 g moL −1 . The drug was launched several years ago and in this short time, the pharmacokinetic properties of firocoxib in dogs and horses have already been well established (Kvaternick et al, 2007a;2007b;Letendre et al, 2008). Firocoxib is available as a chewable tablet oral preparation which has been approved in the European Union for dogs at a once daily administration of 5 mg kg −1 .…”

Section: Firocoxibmentioning

confidence: 99%

“…In addition, firocoxib, as an oral paste was approved by FDA for the control of pain and inflammation associated with osteoarthritis in horses at 0.1 mg kg −1 once daily (Kvaternick et al, 2007b). In dogs, following PO administration (5 mg kg −1 ), firocoxib was well absorbed and eliminated by hepatic metabolism and fecal excretion with an elimination half-life of 8 h (Kvaternick et al, 2007a). Firocoxib in horses (0.1 mg kg −1 ) showed a bioavailability of 79% and an elimination half-life of 30 and 34 h for oral and intravenous administration, respectively.…”

Section: Firocoxibmentioning

confidence: 99%